Wave Life Sciences, Inc.
WVE
Positions held
Your positionsWVE isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $683.76M | Enterprise value | $236.75M | Trailing P/E | — | Forward P/E | -3.00 |
| PEG | — | Price / book | 1.48 | Beta | -1.43 | Dividend yield | 0.00% |
| Revenue growth | -73.9% | Earnings growth | — | Gross margin | -2.0% | Operating margin | -32.5% |
| Profit margin | 0.0% | ROE | -67.4% | ROA | -33.6% | Debt / equity | 0.10 |
| Current ratio | 9.99 | Free cash flow | -$128.78M | Analyst recommendation | strong_buy | Mean target | $18.06 |
| 52w high | $21.73 | 52w low | $3.37 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $2.3M | $38.2M | $17.2M | $7.6M | $8.7M | — |
| Op margin | -3248.3% | -81.8% | -327.4% | -740.7% | -606.5% | — |
| Net income | -$69.4M | -$26.1M | -$53.2M | -$53.9M | -$50.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$73.8M | -$31.3M | -$56.5M | -$56.4M | -$52.8M | — |
- Revenue -94% vs prior quarter ($2.3M vs $38M).
- Operating margin compressed to -3248.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $42.7M | $108M | $113M | $3.6M |
| Op margin | -504.1% | -101.9% | -60.0% | -4459.3% |
| Net income | -$204M | -$97.0M | -$57.5M | -$162M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$215M | -$110M | -$68.0M | -$163M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
2026-10-01 · Lilly, Foghorn part ways; Wave’s FDA-approved plans
2026-10-01 · Wave Life Sciences Says FDA Feedback Supports Registrational Pathway for WVE-006
2026-10-01 · Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
2026-10-01 · Ladenburg Thalmann Initiates Wave Life Sciences at Buy With $10 Price Target
2026-09-30 · Sector Update: Healthcare Stocks Lean Lower Pre-Bell Wednesday
2026-09-30 · Wave Life Sciences Earns $12 Million Milestone as GSK Advances Liver Drug
2026-09-30 · Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
2026-09-28 · 4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-23 · Wave Life Sciences Initiates Phase 2a Trial of Obesity Drug WVE-007 in Combination With Tirzepatide
2026-09-23 · Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
2026-09-22 · Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
Price (daily)
Full chart · RSI · MACD · patterns